Amgen Inc.

AMGN: Somewhat-Bearish (-0.257)

TIKR.com•7/13/2026

Amgen se enfrenta a un plazo del 29 de julio para salvar Tavneos de una retirada de la FDA. Esto es lo que significa para la cotización.

Somewhat-Bullish (0.195)

AMGN: Somewhat-Bullish (0.205)

TradingView•7/13/2026

Perfil del ETF XBI: Dividendos, Rentabilidad (AMEX:XBI)

Somewhat-Bullish (0.277)

AMGN: Somewhat-Bullish (0.227)

Relevancia 0.622

MarketBeat•7/13/2026

Guggenheim emite un pronóstico positivo para el precio de las acciones de Amgen (NASDAQ:AMGN)

Somewhat-Bullish (0.295)

AMGN: Somewhat-Bullish (0.299)

Yahoo Finance Singapore•7/13/2026

Amgen Inc. (AMGN) es una acción en tendencia: hechos que debes conocer antes de apostar por ella

Neutral (0.122)

AMGN: Neutral (0.145)

Investing.com Canada•7/13/2026

Guggenheim sube el precio objetivo de la acción de Amgen a $343 por la combinación de productos

Guggenheim ha incrementado su precio objetivo para Amgen Inc. (NASDAQ:AMGN) a $343 desde $340, manteniendo una calificación Neutral, de cara a los resultados de la segunda trimestre de 2026 de la compañía. La firma ajustó sus estimaciones de ventas y EPS para el 2T y para todo el año 2026, reflejando tendencias de guiones (script) más débiles de lo anticipado para algunos productos y un desempeño más sólido en otros. La actualización contempla un desempeño mixto de los productos, incluyendo una aceleración de la erosión de ventas de los productos de denosumab debido a la entrada de biosimilares, a la vez que incorpora discusiones recientes con la dirección de Amgen y el análisis de la tendencia de los guiones de IQVIA.

Somewhat-Bullish (0.229)

AMGN: Somewhat-Bullish (0.197)

Investing.com Nigeria•7/13/2026

BofA sube el precio objetivo de la acción de Amgen sobre la ejecución de la franquicia de crecimiento Por Investing.com

BofA Securities aumentó su precio objetivo para Amgen Inc. (NASDAQ: AMGN) a $312 desde $307, manteniendo una calificación Neutral, citando una ejecución sólida en las principales franquicias de crecimiento. A pesar de un panorama modesto a corto plazo con ingresos proyectados de $9.38 mil millones para el 2T, se considera que Amgen está infravalorada en función de su bajo P/E frente al crecimiento de ganancias a corto plazo. La firma prevé que 2026 se centrará en la ejecución antes de los importantes resultados de la cartera (pipeline) en 2027, incluyendo MariTide y olpasirán, y a la vez señala la actividad reciente en torno al fármaco para enfermedad rara Tavneos.

Neutral (0.040)

AMGN: Neutral (0.003)

Relevancia 0.344

PR Newswire•7/13/2026

Armata Pharmaceuticals recibe un acuerdo de la FDA sobre el plan inicial de estudio pediátrico para AP-SA02 para el tratamiento de la bacteriemia complicada por Staphylococcus aureus

Armata Pharmaceuticals ha recibido el acuerdo de la FDA sobre un Plan Inicial de Estudio Pediátrico (iPSP) para AP-SA02, una terapia para la bacteriemia complicada por Staphylococcus aureus. Este hito es crucial para la futura presentación de una Solicitud de Licencia de Biológicos (Biologics License Application) y permite ampliar el desarrollo a pacientes pediátricos, con el objetivo de aquellos de hasta 17 años con la misma indicación que los adultos. Los estudios pediátricos se pospondrán hasta que haya datos de seguridad y eficacia de la Fase 3 en adultos, y el estudio de Fase 3 está planificado para finales de 2026.

Somewhat-Bullish (0.221)

AMGN: Neutral (0.147)

Relevancia 0.537

Investing.com•7/13/2026

BofA raises Amgen stock price target on growth franchise execution

BofA Securities has increased its price target for Amgen Inc. (NASDAQ:AMGN) to $312 from $307, while maintaining a Neutral rating, citing strong execution in its growth franchises. Despite the biotech giant trading above this target at $363.39, an InvestingPro tip suggests it appears undervalued given its low P/E ratio relative to near-term earnings growth. The firm’s revenue and EPS projections for Q2 are slightly below consensus, with a significant focus on pipeline readouts anticipated in 2027.

Neutral (-0.122)

AMGN: Somewhat-Bullish (0.289)

Clinical Trials Arena•7/13/2026

GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial

GSK's partner Hansoh Pharma has announced that its antibody-drug conjugate (ADC), risvutatug rezetecan (Ris-Rez), met all primary and key secondary endpoints in a Phase III trial for advanced or relapsed small-cell lung cancer (SCLC) in China. The trial showed significant improvements in overall survival and progression-free survival compared to standard chemotherapy, making it the first positive Phase III OS data for a B7-H3-targeted ADC. GSK, which holds exclusive license rights outside of Greater China, plans further global development,

Bullish (0.434)

AMGN: Somewhat-Bullish (0.315)

Relevancia 0.617

MarketBeat•7/13/2026

J. Safra Sarasin Holding AG Sells 38,033 Shares of Amgen Inc. $AMGN

J. Safra Sarasin Holding AG reduced its stake in Amgen Inc. by 15.5% in the first quarter, selling 38,033 shares and now owning 207,680 shares valued at $73,072,000. Despite this, several other institutional investors increased their holdings in Amgen, and the company reported strong financial results, beating analyst earnings estimates and providing a positive FY 2026 guidance. Analyst ratings for Amgen are mixed, with a consensus "Hold" rating and a target price of $355.73, and insider selling has also been noted.

Somewhat-Bearish (-0.186)

AMGN: Somewhat-Bearish (-0.218)

MarketBeat•7/13/2026

Absher Wealth Management LLC Trims Stock Holdings in Amgen Inc. $AMGN

Absher Wealth Management LLC reduced its stake in Amgen Inc. by 4.4% in the first quarter, now holding 74,920 shares valued at $26.36 million, making Amgen its 19th largest holding. Other institutional investors also adjusted their positions, with IFC Advisors LLC boosting holdings by 2.2% and Global Assets Advisory LLC by 6.9%. An insider, SVP Nancy A. Grygiel, sold 1,237 shares of Amgen stock in May, valued at over $400,000.

Neutral (0.078)

AMGN: Neutral (0.079)

Stockhead•7/13/2026

Health Check: Immutep shares bounce on revived lung cancer treatment hopes

Immutep (ASX:IMM) shares surged 30% after releasing positive overall survival data from its INSIGHT-003 lung cancer study, offering renewed hope for its eftilagimod alfa treatment. This comes after the previous TACTI-004 trial was discontinued due to a futility analysis. The company plans to unveil more results soon and is investigating why the TACTI-004 trial failed to meet expectations.

Somewhat-Bullish (0.229)

AMGN: Neutral (0.103)

Relevancia 0.612

Castleview Partners LLC Has $2.77 Million Position in Amgen Inc. $AMGN

Castleview Partners LLC reduced its stake in Amgen Inc. by 37.7% in the first quarter, now holding 7,860 shares valued at $2.77 million. Despite this, other hedge funds increased their positions, and Amgen reported strong Q1 results, exceeding EPS and revenue estimates. The stock currently holds a "Hold" rating from analysts, with an average price target of $355.73.

Neutral (0.121)

AMGN: Neutral (0.102)

Amgen Inc. $AMGN Shares Acquired by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 1.7% during the first quarter, now holding 319,238 shares valued at $112.324 million. Other institutional investors have also adjusted their positions in Amgen, with 76.50% of the stock currently owned by institutional investors. An Amgen SVP recently sold 1,237 shares for over $400,000, reducing their stake by 15%, while analysts have issued various ratings for the stock, with a consensus "Hold" rating and an average target price of $355.73.

Neutral (0.011)

AMGN: Neutral (0.009)

Relevancia 0.303

Cullinan Associates Inc. Has $8.98 Million Stock Holdings in Amgen Inc. $AMGN

Cullinan Associates Inc. decreased its stake in Amgen Inc. by 18.1% in the first quarter, now holding 25,516 shares valued at approximately $8.98 million. Despite this reduction, Amgen reported strong quarterly results, with EPS of $5.15 and revenue of $8.62 billion,

Neutral (0.080)

AMGN: Neutral (0.095)

Relevancia 0.970

Fifth Third Bancorp Acquires 167,835 Shares of Amgen Inc. $AMGN

Fifth Third Bancorp significantly increased its stake in Amgen Inc. by 57.2% in the first quarter, purchasing an additional 167,835 shares and growing its total holdings to 461,207 shares valued at $162.3 million. Amgen's stock traded essentially flat, while the company reported strong Q1 earnings, beating analyst estimates for both EPS and revenue. Analysts currently maintain a consensus "Hold" rating for Amgen with an average price target of $355.73.

Somewhat-Bullish (0.168)

AMGN: Somewhat-Bullish (0.264)

ad-hoc-news.de•7/12/2026

Amgen stock steadies as the biotech group leans on scale

Amgen Inc. (AMGN) maintains its profile as a large-cap biotechnology company with a diversified portfolio in inflammation, oncology, and cardiovascular care. The company's business model relies on marketed therapies, providing a more stable revenue base compared to smaller biotech firms focused on experimental assets. This strategic approach emphasizes operating execution and pricing power, making Amgen a defensive option for investors seeking biotechnology exposure without high binary clinical-event risk.

Somewhat-Bullish (0.260)

AMGN: Somewhat-Bullish (0.297)

MarketBeat•7/11/2026

Candriam S.C.A. Raises Holdings in Amgen Inc. $AMGN

Candriam S.C.A. increased its stake in Amgen Inc. by 0.9% in the first quarter, now owning 395,351 shares worth $139.1 million. Other institutional investors like Vanguard Group Inc., State Street Corp, and Capital World Investors also significantly boosted their holdings in Amgen. The company's stock has shown recent price performance, and analysts have issued various ratings, with a consensus "Hold" and a price target of $355.73.

Somewhat-Bullish (0.319)

AMGN: Somewhat-Bullish (0.304)

MarketBeat•7/11/2026

Conning Inc. Has $33.85 Million Position in Amgen Inc. $AMGN

Conning Inc. has reduced its stake in Amgen Inc. by 5.4% in the first quarter, selling 5,475 shares but still holding 96,214 shares valued at $33.85 million. Despite Conning's reduction, institutional ownership of Amgen remains high at 76.5%, with several other firms increasing their positions. Amgen also surpassed quarterly expectations with strong EPS and revenue, maintaining an average "Hold" rating from analysts.

Neutral (0.131)

AMGN: Somewhat-Bullish (0.298)

ad-hoc-news.de•7/11/2026

Argenx stock reflects biotech growth story amid global autoimmune focus

Argenx, a biotech company specializing in antibody-based treatments for autoimmune diseases, is positioned in the high-risk, high-reward segment of global biotech with a dual listing on Euronext Brussels and Nasdaq. The company's focus on precision medicine and long-term care for chronic autoimmune diseases aims to generate recurring revenue streams through its pipeline of antibody engineering programs. Investors monitor clinical trial outcomes, regulatory approvals, and commercialization strategies, balancing these risks with the potential for significant rewards from innovative therapies addressing unmet medical needs.

Somewhat-Bullish (0.184)

AMGN: Neutral (0.119)

Relevancia 0.609

TradingView•7/10/2026

ETFs Investing in Amgen Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold shares of Amgen Inc. stocks, providing details such as market value, weight of Amgen in the fund, issuer, management style, expense ratio, AUM, price change, and 3-year NAV total return. The ETFs cover a range of investment styles including total market, large cap, high dividend yield, and sector-specific focuses like health care and biotechnology. This information helps investors identify funds offering diversified exposure to Amgen Inc. while managing risk.

Neutral (0.034)

AMGN: Neutral (0.006)

Relevancia 0.313

Quartr•7/10/2026

Veradermics (MANE) Jefferies Global Healthcare Conference 2026 Summary

This article summarizes Veradermics' presentation at the Jefferies Global Healthcare Conference 2026, highlighting the significant market opportunity for a new hair loss treatment. The company's oral therapy, VDPHL01, showed positive Phase II/III clinical trial results with high patient satisfaction and a strong safety profile. Veradermics plans to strategically commercialize the product by targeting distinct patient segments and leveraging digital acquisition strategies, aiming to address the substantial unmet need in the hair loss market.

Somewhat-Bullish (0.295)

AMGN: Neutral (0.141)

Relevancia 0.550

MarketBeat•7/10/2026

Munich Reinsurance Co Stock Corp in Munich Sells 2,916 Shares of Amgen Inc. $AMGN

Munich Reinsurance Co Stock Corp in Munich significantly reduced its stake in Amgen Inc. by selling 2,916 shares, decreasing its position by 83.8% to 563 shares worth $198,000. This comes as other institutional investors like Vanguard Group Inc., State Street Corp, and Capital World Investors either increased their holdings or established new positions in Amgen. The article also notes recent insider selling by Amgen's SVP and provides financial details, recent earnings, and analyst ratings for the company.

Neutral (0.021)

AMGN: Neutral (0.053)

MarketBeat•7/10/2026

Ibex Wealth Advisors Increases Stake in Amgen Inc. $AMGN

Ibex Wealth Advisors has significantly increased its stake in Amgen Inc. by 51.3% in the first quarter, now holding 43,734 shares valued at $15.4 million. This move comes as Amgen reported stronger-than-expected quarterly earnings with an EPS of $5.15 and revenue of $8.62 billion. Despite a mixed outlook from analysts, with a consensus "Hold" rating and a price target of $355.73, several firms have recently raised their price targets for the biotechnology company.

Somewhat-Bullish (0.318)

AMGN: Somewhat-Bullish (0.350)

MarketBeat•7/10/2026

Amgen Inc. (NASDAQ:AMGN) Receives Average Recommendation of "Hold" from Analysts

Amgen Inc. (NASDAQ:AMGN) has received an average "Hold" rating from thirty brokerages, with an average 12-month price target of $355.73. The company recently reported strong quarterly results, exceeding EPS and revenue estimates, and reiterated its FY2026 EPS guidance. While insider selling by an SVP was noted, institutional investors showed mixed activity, with some increasing their stakes.

Somewhat-Bullish (0.294)

AMGN: Somewhat-Bullish (0.289)

scanx.trade•7/10/2026

Ryoncil revenue hits US$36M in Q4, FY26 total at US$115M

Mesoblast Limited announced strong Ryoncil net revenue, reaching US$36 million in Q4 FY26 and US$115 million for the full fiscal year, exceeding projections due to high U.S. pediatric demand. CEO Dr. Silviu Itescu confirmed the company's robust capital position, fueled by revenue growth and new financing, which will support strategic initiatives like label extensions and further product development. Ryoncil is the only FDA-approved treatment for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD), with development ongoing for additional inflammatory diseases and the rexlemestrocel-L platform for heart failure.

Somewhat-Bullish (0.272)

timothysykes.com•7/9/2026

AMGN: Neutral (0.133)

Relevancia 0.591

Amgen Inc. (AMGN) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Amgen Inc. (AMGN) stock, showing its current price of $366.56 with a slight decrease of $1.54 (-0.42%). It also indicates that there are currently no analyst ratings or earnings information available for Amgen Inc. The article also contains extensive disclaimers about the risks of day trading and general investment advice.

Neutral (0.067)

AMGN: Neutral (0.068)

MarketWatch•7/9/2026

Amgen Inc. stock outperforms competitors despite losses on the day

Amgen Inc. (AMGN) stock decreased by 1.19% to $363.62 on Thursday, marking its second consecutive day of losses. Despite this decline, the stock outperformed the broader market, which saw the S&P 500 Index rise by 0.81% and the Dow Jones Industrial Average increase by 0.27% during the same trading session.

Neutral (0.042)

Simply Wall Street•7/9/2026

AMGN: Neutral (0.025)

Relevancia 0.344

Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative

Precigen (PGEN) has been removed from several Russell indexes, which could impact its trading volumes and pricing despite strong recent stock performance. The company's stock is currently considered 55.3% undervalued by analysts, with a fair value estimate of $12.45, largely driven by the rapid uptake of its PAPZIMEOS treatment. However, its high P/B ratio of 98x compared to an industry average of 2.8x raises concerns about potential valuation risk, especially for a company that is still loss-making.

Neutral (0.117)

AMGN: Neutral (0.127)

Relevancia 0.621

Amgen•7/9/2026

How AI Is Changing Drug Discovery and What It Will Take to Unlock Its Full Potential

Artificial intelligence (AI) is transforming drug discovery by helping researchers analyze complex data, generate hypotheses, and identify patterns, but it is not a shortcut. Key challenges remain, including predicting drug behavior in the human body and ensuring safety, requiring progress to link insights across the entire lifecycle of a molecule. The future of AI in drug discovery hinges on high-quality data, biological understanding, and collaboration across scientific disciplines, ultimately aiming to accelerate the development of new medicines for patients.

Bullish (0.414)

AMGN: Bullish (0.439)

24/7 Wall St.•7/9/2026

OZEM Archives

This page provides news and articles related to the Roundhill GLP-1 & Weight Loss ETF (OZEM). It features current stock data for OZEM and highlights an article discussing two major drugmakers dominating the obesity market and how one fund invests in both. The page also includes other financial articles, primarily focused on personal finance topics like mortgage payments and pension planning.

Bullish (0.389)

AMGN: Bullish (0.446)

Relevancia 0.700

Yahoo Finance•7/9/2026

Truist Raises its Price Target on Amgen (AMGN)

Truist has raised its price target on Amgen (AMGN) to $340 from $327, citing expectations for a Q2 rebound in biotech, strong commercial franchises, and a robust catalyst calendar. This follows a previous price target raise by Mizuho analyst Salim Syed. However, Morgan Stanley recently lowered its price target to $333, maintaining an Equal Weight rating but noting potential benefits from broader market leadership and lower interest rates for the biotech sector.

Neutral (0.146)

AMGN: Somewhat-Bullish (0.283)

Trefis•7/9/2026

IVE Hit A New High. Is It Time To Act?

The iShares S&P 500 Value ETF (IVE) has reached a new 52-week high, prompting investors to consider whether to sell. Despite the fund's current valuation being higher than its 5-year median, its diversification and broad participation in the rally suggest that "doing nothing" might be the most effective strategy. The article recommends holding unless the position has exceeded a planned allocation, and suggests using analytical tools to compare IVE against other ETFs for optimal performance.

Somewhat-Bullish (0.188)

AMGN: Somewhat-Bullish (0.308)

Relevancia 0.614

24/7 Wall St.•7/9/2026

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

This article examines investment options for capitalizing on the booming GLP-1 obesity drug market, dominated by Eli Lilly and Novo Nordisk. While the broad Health Care Select Sector SPDR Fund (XLV) offers diluted exposure, the specialized LeaderShares Dr. Bill Grace Global Obesity ETF (OZEM) provides more concentrated holdings in these key drugmakers. However, direct investment in companies like Eli Lilly has significantly outperformed both ETFs, highlighting trade-offs between diversification and focused growth.

Somewhat-Bullish (0.233)

AMGN: Neutral (0.115)

Relevancia 0.704

Ad-hoc-news.de•7/9/2026

X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing

X4 Pharmaceuticals, trading on Nasdaq as XFOR, is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare primary immunodeficiency and related disorders. Its strategy centers on niche medical needs and orphan drug designation, providing specialized treatments for conditions with limited options. The company's pipeline and clinical trial outcomes are critical for investors, as success in specific programs can significantly impact its valuation, particularly as it relies on external financing as a clinical-stage biotech.

Somewhat-Bullish (0.156)

AMGN: Neutral (0.137)

Relevancia 0.584

Barchart.com•7/9/2026

Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme

The Myasthenia Gravis (MG) market is projected to grow significantly from USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by new therapies and increased awareness. Key market players like Argenx, Alexion, AstraZeneca, and Novartis are developing innovative treatments, including efgartigimod alfa-fcab (Vyvgart) and nipocalimab, which are expanding treatment options for various MG serotypes. The report highlights emerging therapies, market dynamics, epidemiological trends, and opportunities within the 7MM (United States, EU4, United Kingdom, and Japan).

Somewhat-Bullish (0.278)

AMGN: Somewhat-Bullish (0.342)

Relevancia 0.627

Barchart.com•7/9/2026

Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme

The Myasthenia Gravis (MG) market is projected to grow significantly from USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by emerging therapies and increased awareness. Key market players like Argenx, Alexion, and UCB Biopharma are developing new treatments, including expanded indications for efgartigimod alfa-fcab (Vyvgart) and zilucoplan. The report highlights recent FDA approvals and promising clinical trial results for various therapies, focusing on advancements in addressing different MG serotypes and improving patient outcomes.

Somewhat-Bullish (0.288)

AMGN: Somewhat-Bullish (0.270)

Relevancia 0.707

Reuters•7/9/2026

India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice

Torrent Pharmaceuticals is voluntarily recalling specific batches of its Semalix semaglutide injection pens. This action follows a product recall notification issued by its manufacturer, Dr. Reddy's Laboratories. The recall concerns select semaglutide pens, a drug used for diabetes treatment.

Somewhat-Bearish (-0.240)

AMGN: Somewhat-Bearish (-0.234)

Relevancia 0.582

MarketBeat•7/9/2026

Sumitomo Mitsui Trust Group Inc. Lowers Holdings in Amgen Inc. $AMGN

Sumitomo Mitsui Trust Group Inc. significantly reduced its stake in Amgen Inc. by 4.6% in the first quarter, selling over 74,000 shares. Despite this, other institutional investors increased their holdings, and overall hedge funds own 76.50% of the company. The article also details recent analyst ratings, Amgen's financial performance, and insider trading activity, noting a recent stock sale by SVP Nancy A. Grygiel.

Neutral (-0.121)

AMGN: Neutral (-0.123)

MarketBeat•7/9/2026

Resona Asset Management Co. Ltd. Raises Position in Amgen Inc. $AMGN

Resona Asset Management Co. Ltd. increased its stake in Amgen Inc. by 2.1% in the first quarter, acquiring an additional 3,704 shares. This brings their total holding to 176,626 shares

Neutral (0.055)

AMGN: Neutral (0.065)

Relevancia 0.977

MarketBeat•7/9/2026

Greenwood Capital Associates LLC Boosts Stock Holdings in Amgen Inc. $AMGN

Greenwood Capital Associates LLC significantly increased its stake in Amgen Inc. by 115.5% in the first quarter, now holding over 30,000 shares valued at $10.7 million. Amgen also reported strong first-quarter earnings, exceeding analyst expectations, and provided optimistic FY 2026 EPS guidance. Despite mixed analyst ratings and ongoing concerns about potential drug recalls and pricing risks, institutional investors continue to adjust their positions in the medical research company.

Neutral (0.101)

AMGN: Neutral (0.107)

The Globe and Mail•7/9/2026

Amgen (AMGN): Buy, Sell, or Hold Post Q1 Earnings?

Amgen has seen a 12% stock gain in the last six months, outpacing the S&P 500's 7.7% return. The biotechnology company demonstrates strong long-term revenue growth and excellent free cash flow margins, indicating a robust operational performance. However, a declining return on invested capital suggests new investments are not yet yielding expected returns, which warrants careful consideration despite the company's overall positive attributes.

Bullish (0.416)

AMGN: Somewhat-Bullish (0.303)

TradingView•7/9/2026

Amgen (AMGN): Buy, Sell, or Hold Post Q1 Earnings?

Amgen (AMGN) has kept pace with the market, gaining 12% in the last six months, slightly outperforming the S&P 500. The biotechnology company shows strong long-term revenue growth and excellent free cash flow margins, indicating a healthy financial state and ability to reinvest. However, a declining return on invested capital (ROIC) suggests that recent investments may not yet be yielding expected results, warranting careful consideration despite overall positive aspects.

Somewhat-Bullish (0.307)

AMGN: Somewhat-Bullish (0.337)

Relevancia 0.960

Moomoo•7/9/2026

RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370

RBC Capital has reiterated its Buy rating on Amgen (AMGN.US) and maintained its target price at $370. This indicates a continued positive outlook from the analyst firm on the biotechnology company's stock performance.

Bullish (0.411)

AMGN: Bullish (0.442)

Simply Wall Street•7/8/2026

Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment

Moderna has settled a patent dispute with Arbutus Biopharma and Genevant Sciences concerning the lipid nanoparticle technology used in its COVID-19 vaccine, agreeing to a $950 million upfront payment. This settlement resolves multi-year litigation, removes legal uncertainty, and allows Moderna to focus on its broader mRNA pipeline. Investors should consider the impact of this payment on Moderna's financials and its high valuation signals.

Neutral (0.131)

Simply Wall Street•7/8/2026

AMGN: Neutral (0.027)

Relevancia 0.551

Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run

Neurocrine Biosciences (NBIX) has returned 89.9% over the past five years, with its stock now appearing closer to fair value than a clear bargain. The company's P/E ratio is 26.8x, slightly above the biotech industry average, but close to its tailored fair P/E of 28.0x, indicating it's trading at a roughly fair earnings multiple. Future performance will depend on the durability of existing products and the successful execution of its pipeline, particularly without significant clinical or regulatory setbacks.

Neutral (0.045)

AMGN: Neutral (0.029)

Relevancia 0.627

D Magazine•7/8/2026

Meet the Dallas 500: Brian Tyler, McKesson

Brian Tyler, CEO of McKesson, shares his insights on leadership, the importance of AI in healthcare, and his strategies for success. He highlights McKesson's achievements in expanding patient support through oncology and biopharma platforms and discusses the qualities he seeks in leaders, such as curiosity, humility, and sound judgment. Tyler also touches on his personal habits, like daily exercise, and a favorite podcast, "Acquired," for business lessons.

Bullish (0.354)

AMGN: Somewhat-Bullish (0.346)

Relevancia 0.630

The Globe and Mail•7/8/2026

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH?

This article compares two healthcare ETFs, Invesco Nasdaq Biotechnology ETF (IBBQ) and State Street SPDR S&P Pharmaceuticals ETF (XPH), to determine which is the better buy for investors. IBBQ offers a lower expense ratio, higher dividend yield, and broader diversification across 253 companies, while XPH has delivered higher 1-year total returns and focuses on 65 pharmaceutical companies with an equal-weighted approach. The analysis concludes that IBBQ is generally more suitable for long-term investors due to its lower cost and broader exposure, while XPH is a more targeted bet for those with specific conviction in the pharmaceutical sub-sector.

Neutral (0.150)

AMGN: Neutral (0.122)

Relevancia 0.672

AD HOC NEWS•7/8/2026

Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects

Oramed Pharmaceuticals is drawing investor attention due to its oral drug delivery platform, which aims to develop capsule-based alternatives to injectable biologic drugs. The Nasdaq-listed biotech focuses on clinical-stage development, with a notable project being an oral insulin capsule for diabetes. Investors are monitoring milestone events, regulatory feedback, and potential collaborations, as the company works to advance and monetize its oral drug delivery technology.

Somewhat-Bullish (0.151)